Takeda’s dengue data spell more bad news for Sanofi – Vantage

Takeda’s pivotal trial has suggested that TAK-003 could work in both dengue-naïve and previously infected patients, making Sanofi’s Dengvaxia look irrelevant.

Read More »

Leave a Reply